Phase 4 N=25 Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis Patients
Rheumatoid Arthritis
Primary: PDUS — 28.68; 19.52; 12.17 units on a scale — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=120 Telephone Counseling for Tobacco Cessation
Tobacco Use Cessation
Primary: The Percentage of Self-reported Tobacco Cessation Attempts Between Groups — 8; 5 participants
Phase 2 N=15 Antiglucocorticoid Therapy for Cognitive Impairment in Late-life Anxiety Disorders
Anxiety Disorders
Primary: Drug Acceptability, as Measured by Number of Participants With Dose-limiting Side Effects — 1 Participants
Phase 1 N=190 Pharmacokinetics, Safety, and Tolerability Study of the Pen and PFS of SB5 in Healthy Subjects
Healthy
Primary: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) — 2743.2; 2503.3 h·μg/mL
Phase 1 N=15 A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet Formulation
Healthy Volunteers
Primary: Cmax: Maximum Observed Plasma Concentration for TAK-831 — 650.04; 865.48 nanogram per milliliter (ng/mL) — p=0.0058
Phase 1 N=6 Absorption and Elimination of Radiolabeled Daprodustat
Anaemia
Primary: Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-Inf]) of Total Drug-related Material (Radioactivity) in Plasma…
Phase 3 N=18,924 ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
Atherosclerotic Cardiovascular Disease
Primary: Time to First Occurrence of Major Adverse Cardiovascular Event (MACE); Percentage of Observed Participants With Outcome Measure Events During the Study — 11.1; 9.5…
N/A N=66 Pain Perception With Tenaculum Placement
Pain
Primary: Pain With Tenaculum Placement — 44; 32 units on a scale
N/A N=496 Educating and Supporting Primary Care Providers in the Implementation of Evidence-based Practices for ADHD
Attention Deficit Hyperactivity Disorder
Primary: Number of Patients Who Were Sent the Parents Rating Scale — 33; 37 Participants
Phase 2 N=50 A Study to Evaluate Safety and Tolerability of MIV-711 in Osteoarthritis Patients
Osteoarthritis, Knee
Primary: Safety and Tolerability of MIV-711 in Osteoarthritis (OA) Patients — 21; 2; 2; 0 Participants
Phase 2 N=136 A Multi-Site Study to Evaluate the Safety and Effect of Study Drug on Participants With Rheumatoid Arthritis
Arthritis, Rheumatoid
Primary: Percentage of Participants Achieving American College of Rheumatology 20% Response (ACR20) (Effectiveness of LY2127399 in Treating Rheumatoid Arthritis Using the ACR20…
N/A N=22 Endothelial Function and Cardiac Output in RV Pacing
Bradycardia
Primary: Endothelial Function Assessed by Flow Mediated Vasodilatation — 1.96; 1.73 EndoPAT index (EnFI)
Phase 3 N=235 Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants.
Psoriasis
Primary: Percentage of Secukinumab 300 mg Participants Achieving PASI 75 at 16 Weeks — 65.3 Percentage of participants — p=<0.0001
N/A N=70 RCT of Pulp Capping Over Carious Exposure in Adults
Carious Exposure · Human Permanent First and Second Molars · Mature Teeth
Primary: Survival of Capped Pulps — 842; 1201 Survival days — p=<0.01
Phase 1 N=150 Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001)
Pneumococcal Infections
Primary: Adult: Percentage of Participants With Any Adverse Event — 93.3; 83.3 Percentage of Participants